Phase 3 trial of dovitinib vs sorafenib in patients with metastatic renal cell carcinoma after 1 prior VEGF pathway-targeted and 1 prior mTOR inhibitor therapy R. Motzer,C. Szczylik, N. J. Vogelzang,C. N. Sternberg,C. Porta, J. Zolnierek,C. Kollmannsberger,S. Y. Rha, G. A. Bjarnason,B. Melichar,U. De Giorgi, G. Urbanowitz, C. Cai,M. Shi,B. EscudierEUROPEAN JOURNAL OF CANCER（2013）引用 29|浏览7暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
